Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach

Avalyn Pharma announced the publication of detailed results from two Phase 1 clinical trials of its inhaled antifibrotic drug AP02, aimed at treating idiopathic pulmonary fibrosis (IPF). The results validate the company's approach of delivering antifibrotic medicines directly to the lungs, enhancing local exposure while minimizing systemic effects. Enrollment for the AURA Phase 2 trial is progressing as planned, with topline data expected by late 2027.